Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q4 2016 call → NOWe need to determine if the call conveys that outsiders are currently underweighting something the company has already done, and management points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Key points from management: - Ernest Rady: "Our focus in 2017 continues to be in the growth of the net asset value for our shareholders which we believe will result in increasing cash flow and dividends paid out to our stockholders. We are very pleased with our FFO growth that increased 5% for the year ended December 31, 2016. Our same store cash NOI also increased 5% for the year ended December 31, 2016. We believe that 2017 will be a year of repositioning investment and growth." Then he lists three projects: Torrey Plaza, Oregon Square, Waikele. These are repositioning projects, some in progress. - Bob Barton discusses guidance, adjustments, etc. He mentions Hassalo, Torrey Point, Waikele, etc. - There is a discussion about the ATM issuance and using proceeds for acquisitions. Ernest Rady says: "we took a discount on our estimated NAV in the issuance of that stock but we think that with interest rates rising and perhaps more turbulence than existed over the last couple years we can find an investment for those funds that will be more accretive than the dilution that we experienced." That's about future acquisitions, not something already done. - The question is: does management convey that outsiders are currently underweighting something the company has already done? That is, a recognition gap about an existing asset or action whose payoff is still ahead. Look for statements like "the market doesn't appreciate X" or "analysts are modeling Y but we have Z already." In the transcript, there is a discussion about guidance and consensus. Bob Barton says: "As I look at the current Bloomberg consensus for Q1 2017, I am seeing $0.494 of FFO per share. Our current expectation is that Q1 2017 FFO will be closer to $0.45 per FFO share. I believe the $0.04 per share FFO difference is due to the following." He then lists reasons: Hassalo NOI, ICW lease at Torrey Plaza, dilution from ATM, etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.